Results 251 to 260 of about 14,877 (300)
Trombocitopenia extrema secundaria a abciximab [PDF]
Revista Española de Cardiología, 2004 Los antiagregantes antiglucoproteina IIb/IIIa bloquean la union del fibrinogeno y el factor de Von Willebrand a sus receptores. Pueden causar hemorragia y trombocitopenia. Se ha analizado la incidencia y la repercusion clinica de la trombocitopenia extrema severa (< 20.000 por µl) secundaria a abciximab en un estudio prospectivo de 375 pacientes (el 74%
Dolores M. Arias Garcia +5 more
openaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Understanding the complexity of abciximab-related thrombocytopenia
Thrombosis and Haemostasis, 2010Patients with a rare bleeding disorder characterised by skin and mucosal bleeding – typical of thrombocytopenia – but with a normal platelet count, and later characterised by a defective aggregation to all agonists, described as Glanzmann thrombasthenia, have mutations in a platelet membrane glycoprotein (GP) called GP IIb/IIIa, also known as the ...
De Caterina R, Zimarino M.
openaire +5 more sources
Visual compatibility of abciximab with selected drugs
American Journal of Health-System Pharmacy, 2002(March 1, 2002, Letter). In the table on page 466, the concentration of fentanyl citrate should be 0.05 mg/mL.
Steven Baroletti +2 more
openaire +3 more sources
Alveolar Hemorrhage as a Complication of Treatment With Abciximab
Chest, 2001The use of abciximab, a chimeric monoclonal antibody Fab fragment specific for platelet glycoprotein IIb/IIIa receptors, is associated with improved outcome after angioplasty and stent placement. Major complications include bleeding, but pulmonary hemorrhage has been reported rarely.
Malcolm R. Bell +2 more
openaire +3 more sources
Thrombocytopenia associated with c7E3 Fab (abciximab)
Annals of Hematology, 2002Abciximab (c7E3 Fab) inhibits platelet aggregation and is used to prevent complications of percutaneous coronary intervention. Thrombocytopenia is an often-cited complication of abciximab. Pseudothrombocytopenia is due to ethylenediaminetetraacetate (EDTA)-activated platelet agglutination, resulting in a spuriously low platelet count. We have looked at
Anil Potti +3 more
openaire +3 more sources
Abciximab: A New Antiaggregant Used in Angioplasty
Annals of Pharmacotherapy, 1996OBJECTIVE: To review the scientific literature on the pharmacology and clinical uses of abciximab. DATA SOURCES: MEDLINE, Index Medicus, and bibliographic literature searches of English-language articles pertaining to abciximab, 7E3, m7E3, and c7E3 were performed.
Vincent F. Mauro, Tina B Genetta
openaire +3 more sources
In vivo demonstration of an antithrombin effect of abciximab
The American Journal of Cardiology, 2000Abciximab prolonged the activated clotting time (ACT) in a post hoc analysis from the Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications trial and an in vitro study has suggested an antithrombin effect of platelet glycoprotein IIb/IIIa inhibition. The purpose of this study was to evaluate the in vivo effects of
Jean-Pierre M. Geagea +11 more
openaire +3 more sources
Extreme Thrombocytopenia Following Abciximab Therapy
Revista Española de Cardiología (English Edition), 2004Antagonists of the glycoprotein IIb/IIIa receptor block the binding of fibrinogen and Von Willebrand factor to the platelet receptor. This effect can lead to bleeding and thrombocytopenia. We analyzed the incidence and clinical repercussions of severe thrombocytopenia (< 20 000 /microl) secondary to abciximab treatment in a prospective study of 375 ...
Miguel A. Prieto Palomino +5 more
openaire +3 more sources
Delayed immunologic thrombocytopenia induced by abciximab
Thrombosis and Haemostasis, 2004SummaryAbciximab is an anti-GPIIb-IIIa drug widely used to prevent thrombotic complications during percutaneous coronary intervention. We now report on the immunologic origin of thrombocytopenia developing between 7 and 12 days after the onset of abciximab infusion.
Emilse Bermejo +6 more
openaire +3 more sources